ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferon"

  • Abstract Number: 1922 • ACR Convergence 2023

    Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol

    Charline Vauchy1, Maxime Desmarets1, Paul Bastard2, Anne Puel2, Pascale Richard3, Jean Laurent Casanova2, Pierre Tiberghien3, Eric Toussirot4 and Francois Aubin5, 1INSERM CIC-1431, Besançon, France, 2IHU Imagine, AP-HP Necker, Paris, France, 3Etablissement Français du Sang, St. Denis, France, 4University Hospital of Besancon, Besançon, France, 5Dermatology, University Hospital of Besancon, Besançon, France

    Background/Purpose: Hidradenitis suppurativa (HS) is a multifactorial auto-inflammatory disorder with a prevalence of 1% in North American and European populations. HS may be associated with…
  • Abstract Number: 0205 • ACR Convergence 2023

    Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy

    Jamie Chieh Lo1, Ying-Nan Tsai2, Cheng-Hao Tseng3, Yao-Chun Hsu4 and Song-Chou Hsieh5, 1School of Medicine, I-Shou University, Kaohsiung, Taiwan, 2Department of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, 3Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, 4I-Shou University School of Medicine, E-Da Hospital Center of Liver Diseases, Kaohsiung, Taiwan, 5National Taiwan University Hospital, Taipei, Taiwan

    Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…
  • Abstract Number: 0919 • ACR Convergence 2023

    Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level

    Zoha Faheem1, Giselle Boukhaled2, Kieran Manion1, Carolina Munoz-Grajales3, Carol Nassar1, Michael Kim1, Dafna Gladman4, Murray Urowitz5, Zahi Touma6, David Brooks2 and Joan Wither7, 1Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, 2Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, 3UHN/TWH, Toronto, ON, Canada, 4Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, 6University of Toronto, Toronto, ON, Canada, 7University Health Network, Toronto, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with unpredictable flares interspersed with prolonged periods of disease quiescence. Interferon (IFN) is a hallmark…
  • Abstract Number: 1963 • ACR Convergence 2023

    Effect of JAK-STAT Inhibition by Baricitinib and Tofacitinib on Disease Phenotype in a Mouse Model of Myositis

    Rita Spathis, Sabrina Narvesen, Deeva Robles Kuriplach, Karen Huang, Teja Sundar, Daniel Shulman, Elizabeth Bagley, Kanneboyina Nagaraju and Melissa Morales, Binghamton University, Johnson City, NY

    Background/Purpose: Dysregulation of the interferon (IFN) pathway plays a major role in the pathophysiology of autoimmune myositis. Upregulation of type 1 IFN stimulated genes (an…
  • Abstract Number: 0548 • ACR Convergence 2023

    Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals

    Md Yuzaiful Md Yusof1, Sabih Ul-Hassan1, Zoe Wigston1, Antonios Psarras2, Jack Arnold1, Lucy Carter3, Paul Emery4 and Ed Vital1, 1University of Leeds, Leeds, United Kingdom, 2Oxford University, Oxford, United Kingdom, 3University of Leeds, Hartlepool, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Many rheumatologists find it challenging to safely discharge "At-Risk" ANA-positive people at the first visit due to lack of cardinal signs and prediction tools.…
  • Abstract Number: 0937 • ACR Convergence 2023

    IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice

    Ji Won Yang1, Kun Hee Lee2, Jin Seok Woo2, Ha Yeon Jeong2, JeongWon Choi2, Eui-Jong Kwon1, Mi-La Cho2 and Sung-Hwan Park1, 1Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 2Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: Systemic sclerosis (SS), also known as scleroderma, is a chronic autoimmune disease caused by inflammation, tissue fibrosis, and vasculopathy. Although the pathological mechanisms of…
  • Abstract Number: 2044 • ACR Convergence 2023

    Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population

    Alhanouf Alsaleem, Sulaiman Al-Mayouf and Shahad Alansari, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

    Background/Purpose: IFN-mediated diseases are mendelian innate immunodysregulatory disorders that present early in life with fevers, sterile organ inflammation, and a high type-I IFN-response gene signature…
  • Abstract Number: 0574 • ACR Convergence 2023

    Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE

    Kanwal Zahid Siddiqi1, Amanda Hempel Zinglersen2, Katrine Kjær Iversen1 and Søren Jacobsen2, 1Copenhagen Research Center for Autoimmune Connective Tissue Diseases (COPEACT), Department of Rheumatology 4242, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark, 2Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Aberrant activation of type I IFN, and subsequent adverse clinical implications, have been widely discussed in relation to SLE. With the lack of consistent…
  • Abstract Number: 1176 • ACR Convergence 2023

    Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis

    Jiri Vencovsky1, Jolie Feldman2, Lisa McConnachie2 and Brendan M. Johnson2, 1Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 2Priovant Therapeutics, Durham, NC

    Background/Purpose: Dermatomyositis (DM), an idiopathic inflammatory myopathy, is a chronic and often debilitating condition characterized by a hallmark skin rash (e.g., Gottron's sign and heliotrope…
  • Abstract Number: 2297 • ACR Convergence 2023

    Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis

    Laura Patricia Whittall Garcia1, Dafna Gladman2, Murray Urowitz3, Zahi Touma4 and Joan Wither1, 1University Health Network, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: Type I Interferons (IFN-I) play a role in SLE and Lupus Nephritis (LN) pathogenesis. We have recently shown that IFN-I gene expression predicts the…
  • Abstract Number: 0598 • ACR Convergence 2023

    Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study

    Richard Furie1, Victoria Werth2, Eric Milliman3, Kyle Ferber3, Fergal Casey3, Roland Brown3, Denitza Raitcheva3, Jad Zoghbi3, Danielle Graham3, George Kong3, Youmna Lahoud3, Nathalie Franchimont4 and Catherine Barbey5, 1Northwell Health, Manhasset, NY, 2University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA, 3Biogen, Cambridge, MA, 4Former employee of Biogen, Cambridge, MA, 5Biogen, Baar, Switzerland

    Background/Purpose: Litifilimab is a humanized IgG1 mAb targeting BDCA2, a receptor expressed on plasmacytoid dendritic cells (pDCs), that negatively regulates the production of Type I…
  • Abstract Number: 1240 • ACR Convergence 2023

    Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash

    Ilaria Maccora1, Patricia Vega-Fernandez2, Kimberly Risma3 and Grant Schulert4, 1PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, 2Division of Rheumatology, Cincinnati Children's Hospital, Medical Centre, Cincinnati, OH, 3Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: STING-associated vasculopathy with onset in infancy (SAVI) is characterized by systemic inflammation, skin vasculopathy and interstitial lung disease. However, since the initial description knowledge…
  • Abstract Number: 2329 • ACR Convergence 2023

    AMTX-100, a Nuclear Transport Inhibitor, Attenuates Inflammatory Cytokine Production in vitro and Following UV Mediated Skin Inflammation in a Mouse Model of Cutaneous Lupus Erythematosus in vivo

    Xizhang Sun1, Jie An1, Ting Wang1, Arpit Rathee1, Vernon Alvarez2, Matthew Gonda3, Christian Lood1 and Keith Elkon1, 1University of Washington, Seattle, WA, 2Amytrx Therapeutics Inc., Nashville, TN, 3Amytrx Therapeutics, Nashville, TN

    Background/Purpose: Inflammatory stimuli induce transcription factors (TFs) such as NF-kB and interferon regulatory factors (IRFs). TFs are transported from cytosol to nucleus to activate genes…
  • Abstract Number: 0608 • ACR Convergence 2023

    Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study

    Anca Askanase1, David D'Cruz2, Kenneth Kalunian3, Joan Merrill4, Sandra Navarra5, Clélia Cahuzac6, Peter Cornelisse6, Daniel Strasser6, Luba Trokan7 and Ouali Berkani8, 1Columbia University Medical Center, New York, NY, 2Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, 3University of California San Diego, La Jolla, CA, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, 6Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, 7Idorsia Pharmaceuticals Ltd. at time of data generation, Allschwil, Switzerland, 8IDORSIA, Allschwil, Switzerland

    Background/Purpose: Cenerimod is an orally active, selective sphingosine 1-phosphate (S1P) 1 receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). In the…
  • Abstract Number: 1271 • ACR Convergence 2023

    Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)

    Bong-Ki Hong1, Sungyong You2, Naeun Lee1, Jung Gon Kim3, Kijun Lee4, Ji Hyeon Ju5, Wan-Uk Kim1 and Ho-Youn Kim6, 1The Catholic University of Korea, Seoul, South Korea, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3Inje University Ilsan Paik Hospital, Goyang, South Korea, 4YiPSCELL, Secho, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 6HoYoun Kim's Clinic for Arthritis Rheumatism, Seoul, South Korea

    Background/Purpose: Recent research has revealed a significant upregulation of IFNγ-related genes in RA patients, though the underlying mechanisms and implications are still unclear. To further…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology